Jun 15, 2020
WuXi Biologics (Suzhou) Received EMA GMP Certificate for Biosafety Testing
Jun 08, 2020
WuXi Biologics Signs Lease for a Clinical Manufacturing Facility in the United States
May 18, 2020
WuXi Biologics Closes Land Deal to Build State-of-the-Art Biologics Production Facility in the United States
Apr 30, 2020
WuXi Biologics and Aravive Form Strategic Collaboration to Develop Novel High-Affinity Bispecific Antibodies Targeting Cancer and Fibrosis Using the WuXiBody(TM) Platform
Apr 21, 2020
WuXi Biologics Completed Acquisition of a Drug Product Manufacturing Facility in Germany
Feb 25, 2020
WuXi Biologics and Vir Biotechnology Announce Collaboration for Global Development of Antibodies to Treat COVID-19
Feb 23, 2020
WuXi Biologics Congratulates Immutep on Positive Interim Data for IMP-321
Feb 18, 2020
WuXi Biologics' Subsidiary WuXi Vaccines Signed Long-Term Vaccine Manufacturing Contract with a Global Vaccine Leader
Feb 11, 2020
WuXi Biologics Provides Back-to-work Operation Update Related to the Coronavirus Outbreak
Jan 28, 2020
WuXi Biologics Enables Development of Multiple Neutralizing Antibodies for Novel Coronavirus
Jan 09, 2020
WuXi Biologics and Almirall Sign Strategic Collaboration Agreement for Multiple Bispecific Antibodies Targeting Dermatology Diseases
Jan 01, 2020
WuXi Biologics Congratulates OncoImmune on FDA Clearance of IND Application for Next Generation anti-CTLA-4 Antibody ONC-392
Dec 23, 2019
WuXi Biologics Receives "Special Award to Investors in Ireland" from Asia Matters
Nov 22, 2019
WuXi Vaccines to Build a $240 Million Manufacturing Facility in Ireland
Nov 18, 2019
WuXi Biologics Congratulates Tychan on the World's First Yellow Fever Antibody Tested Safe and Efficacious in Human Volunteers
Jun 20, 2019
WuXi Biologics to Expand Integrated Biologics Conjugation Solution Center to Include Commercial Manufacturing
Jun 04, 2019
WuXi Biologics Hosts Successful Inaugural Investor Day
May 20, 2019
WuXi Biologics Signed Letter of Intent for Long-Term Vaccine Manufacturing Contract
May 16, 2019
WuXi Biologics Commenced Construction of a 48,000 L Integrated Manufacturing Center for Innovative Biologics in Chengdu
Apr 16, 2019
I-Mab Biopharma and WuXi Biologics Announce Long-term Strategic Manufacturing Partnership for Five Clinical and One Commercial Programs